Amryt Pharma Net Income 2019-2021 | AMYT

Amryt Pharma net income from 2019 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Amryt Pharma Annual Net Income
(Millions of US $)
2020 $-105
2019 $-63
2018 $-30
Amryt Pharma Quarterly Net Income
(Millions of US $)
2021-06-30 $-7
2021-03-31 $-17
2020-12-31 $-47
2020-09-30 $-10
2020-06-30 $-18
2020-03-31 $-29
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.747B $0.183B
Amryt Pharma plc is a biopharmaceutical company. It develops and commercializes therapeutics to treat rare diseases. Amryt Pharma plc is based in London, the United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00